Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Shaperon's EBITDA for the
three
months ended in Mar. 2026 was ₩-3,227.1 Mil. Shaperon's Revenue for the
three
months ended in Mar. 2026 was ₩65.4 Mil. Therefore, Shaperon's EBITDA margin for the quarter that ended in Mar. 2026 was -4,934.40%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Shaperon EBITDA Margin % Related Terms
Shaperon EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Shaperon's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKRX:378800 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Shaperon's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shaperon EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shaperon's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Shaperon's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shaperon (XKRX:378800) has a EBITDA Margin % of -4,934.40% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shaperon and its competitors. According to the industry distribution chart, Shaperon ranks #848 out of 940 companies in the Biotechnology industry, placing it in the top 90.2%.
Is Shaperon's EBITDA Margin % too high?
Shaperon's current EBITDA Margin % is -4,934.40%. Based on the distribution chart, Shaperon ranks #848 out of 940 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Shaperon has a GF Score™ of 31/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Shaperon's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shaperon ranks #848 out of 940 companies for EBITDA Margin %. This places Shaperon in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shaperon and its competitors. Shaperon's current EBITDA Margin % is -4,934.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shaperon stock overvalued right now?
Based on GuruFocus' analysis, Shaperon (XKRX:378800) is currently considered Possible Value Trap. The stock's GF Value™ is ₩4,390.37, compared to a current price of ₩514.00 — trading 88.3% below its estimated fair value. The current EBITDA Margin % is -4,934.40%. Shaperon's overall GF Score™ is 31/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Shaperon (XKRX:378800), the current EBITDA Margin % is -4,934.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shaperon (XKRX:378800) Overvalued in 2026?
Based on GuruFocus' analysis, Shaperon stock appears to be undervalued.
The current stock price of ₩514.00 is trading 88.3% below its estimated GF Value™ of ₩4,390.37.
GuruFocus considers Shaperon to be Possible Value Trap.
Key valuation signals for XKRX:378800:
EBITDA Margin %: -4,934.40%
GF Value™: ₩4,390.37 vs. price of ₩514.00 (88.3% below fair value)
No single metric tells the full story. See the XKRX:378800 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shaperon Inc is a developer of innovative inflammasome inhibitors and nanobody therapeutics intended to develop novel treatments for various chronic inflammatory diseases, including atopic dermatitis, systemic inflammatory response syndrome, neuroinflammatory diseases, and chronic inflammation. It offers a range of drug candidates, including a gel-type atopic dermatitis drug for use in the treatment of systemic inflammatory response syndrome, neuroinflammatory diseases and for treating chronic inflammation. The company also provides immunotherapeutic products and a single-domain neutralizing antibody, enabling clients to improve patient's quality of life by developing safe and efficacious drugs and immunotherapies.
31GF Score
Get the complete analysis for XKRX:378800
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:378800 has been successfully added to your 
